Diabetes device firm Beta Bionics falls on $150 mln equity raise

Senseonics Holdings

16/09/2026 11:26

** Shares of insulin delivery device maker Beta Bionics BBNX.O down 5.6% at $18.15 before the bell after $150 mln overnight follow-on priced
** Irvine, California-based firm late Tues sold ~8.7 mln shares, including ~1 mln pre-funded warrants, at $17.25
** Offering size increased from $125 mln and priced at 10.3% discount to stock's last sale on Tues
** JP Morgan, Piper Sandler, Wells Fargo and Leerink joint bookrunners
** Co intends to use net offering proceeds for general purposes, including for commercialization of Mint, manufacturing facilities expansion, among other uses
** Early Mon, BBNX said the U.S. FDA cleared Mint and it expects to commercially launch its patch pump in Q1 2027. Also, Senseonics SENS.O announced partnership to integrate its Eversense 365 Continuous Glucose Monitoring system with BBNX's iLet Bionic Pancreas system
** At Tues close, BBNX shares shed ~37% YTD; co went public in Jan 2025 IPO priced at $17
** Avg rating of 12 analysts is "buy"; median PT $22, per LSEG

(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))